Lercanidipin Hydrochlorid Actavis

Lercanidipine Hydrochloride, the active ingredient in Lercanidipin Hydrochlorid Actavis, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of essential hypertension in adult patients. GNH USA supplies Lercanidipin Hydrochlorid Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is used to treat hypertension by targeting vascular smooth‑muscle calcium channels.

Essential hypertension: lowers systolic and diastolic blood pressure by causing peripheral vasodilation and reducing systemic vascular resistance.

Lercanidipine Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often occurring early in therapy. - Flushing: sensation of warmth, typically on the face or neck. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially when standing quickly. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause syncope. - Myocardial infarction: rare but reported in susceptible individuals. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or airway requiring urgent care.

Before initiating therapy, clinicians should consider several safety factors. - Blood pressure monitoring: measure baseline and periodic readings to assess response. - Renal impairment: use with caution; adjust if severe dysfunction is present. - Hepatic impairment: consider dose adjustment or close monitoring. - Concomitant CYP3A4 inhibitors: may increase plasma concentrations, requiring vigilance. - Pregnancy and lactation: avoid unless benefits clearly outweigh potential risks. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine Hydrochloride can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase drug exposure. - Grapefruit juice: can elevate plasma levels and precipitate hypotension. - Concurrent use with other potent antihypertensives (e.g., beta‑blockers) may cause excessive blood pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Diuretics: additive hypotensive effect, requiring BP monitoring. - Lithium: potential increase in lithium concentrations, necessitating serum level checks.